Dennis Lawlor, MD
Pulmonary Disease · Olathe, KSNPI 1457326282
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,507 of the $2,051 with a category attached, or 73.5%. Medtronic accounts for 85.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $1,763, more than ten times the $64 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 26 payments — averaging $78.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Olympus America Inc.$52
- Boehringer Ingelheim$52
- Inspire Medical Systems, Inc.$40
- GSK$34
- Pulmonx Corporation$27
- plus $98 from 5 others
What the payments were for
- Travel & lodging$1,50773%
- Food & beverage$50825%
- Education$362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,748 |
| Olympus America Inc. | 1 | $52 |
| Boehringer Ingelheim | 2 | $52 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| GSK | 1 | $34 |
| Pulmonx Corporation | 1 | $27 |
| Itamar Medical Inc | 1 | $25 |
| Healthmyne, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $15 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$1,520
How this compares
$2,051 in reported general payments places this provider in the 50th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $150,462 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $137,541 |
| Fasenra PenBenralizumab | 12 | $63,990 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $62,960 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $45,149 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $32,817 |
| Spiriva RespimatTiotropium Bromide | 33 | $27,298 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $27,198 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $13,566 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $10,355 |
| Pirfenidone | 11 | $7,371 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,989 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $5,669 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $4,335 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 163 | $3,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $34 | $228,477349 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $15 | $69,949100 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $52 | $60,11580 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Olathe
- Ihab HassanOlathe$1K
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Robert SourkHutchinson$33K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Brandon BowersShawnee Mission$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.